Sign up to save your podcasts
Or
Share GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff
We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.
Key topics covered in this episode:
● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer
● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer
● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC
● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer
Tune in for this dense, insightful recap and stay ahead of the curve.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!
#OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast
View all episodes
By Oncology Brothers
4.9
4242 ratings
We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.
Key topics covered in this episode:
● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer
● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer
● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC
● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer
Tune in for this dense, insightful recap and stay ahead of the curve.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!
#OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
122 Listeners
ASCO Daily News
59 Listeners
Pod Save America
87,984 Listeners
Core IM | Internal Medicine Podcast
1,147 Listeners
The ONS Podcast
206 Listeners
OncoPharm
188 Listeners
ASCO Guidelines
48 Listeners
OncLive® On Air
23 Listeners
Lung Cancer Considered
27 Listeners
Oncology Today with Dr Neil Love
61 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
197 Listeners
Oncology for the Inquisitive Mind
4 Listeners